Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRTX849 + Cetuximab vs Chemotherapy in Advanced Colorectal Cancer with KRAS G12C Mutation
NCT04793958Phase 3Active, not recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, open-label trial of adagrasib in colorectal cancer (CRC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Overall Survival at 30 months and Progression-Free Survival at 30 months. Started Jun 2021; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04793958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793958.